Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.27 +0.39 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
31 32 Next >
A Peek Into The Markets: US Stock Futures Higher Ahead Of Earnings, Fed Speakers
Pre-open movers 
Via Benzinga
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
Regeneron-Sanofi's Dupixent Significantly Improved Signs, Symptoms In Chronic Itchy Skin Disease
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) have presented  
Via Benzinga
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection. 
Via Benzinga
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock. The Moderna Analyst: BofA... 
Via Benzinga
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases. 
Via Benzinga
Regulus Moving Closer To Potential $25 Million Milestone Payment For Novel Kidney Disease Treatment Licensed To Sanofi
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Up to 60,000 people in the US with a rare genetic kidney... 
Via Benzinga
Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren& 
Via Benzinga
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
From Seagen Inc.
Via Business Wire
Why Sanofi Shares Are Trading Lower Today
Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer, failed to slow the progression of the disease in... 
Via Benzinga
JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474
JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ: KYMR) with a Neutral rating and a $44 price target. Analyst Eric Joseph says... 
Via Benzinga
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... 
Via Benzinga
Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients
Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001)... 
Via Benzinga
BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC
BioNTech SE (NASDAQ: BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to its FixVac candidate BNT116... 
Via Benzinga
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
Adagene will apply its technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights for two Heidelberg Pharma ADC candidates in... 
Via Talk Markets
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory... 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact
Sanofi SA (NASDAQ: SNY) has signed a collaboration with Adagene Inc (NASDAQ: ADAG) to advance two preclinical immuno-oncology candidates and an option to... 
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios... 
Via Benzinga
DarioHealth Enters Into Strategic Agreement With Sanofi U.S.
Novel Strategic Agreement focuses on commercial growth for Dario and the development of Digital Health Solutions on Dario’s platform. 
Via Talk Markets
Canada Approves First Plant-Based COVID-19 Vaccine
As Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc's (NYSE: GSK) COVID-19 vaccine finally heads to regulators, another shot using GSK's pandemic... 
Via Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline... 
Via Benzinga
A Receding tide
Sanofi and GlaxoSmithKline have developed a new Covid-19 vaccine which they claim is 100% efficient. 
Via Talk Markets
Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.